HaemaLogiX Achieves First Patient Dosing Milestone with Targeted KMCAR™ T-Cell Therapy

A patient in Sydney received an infusion of their own immune cells, genetically engineered to hunt down cancer. The cells were designed to recognize and destroy malignant plasma cells while leaving healthy immune tissue untouched. This happened in late August at Peter MacCallum Cancer Centre, marking the first time a human has been treated with KMCAR™ T-cell therapy—a new approach to multiple myeloma that HaemaLogiX Ltd has spent years developing.

Multiple myeloma is the second-most common blood cancer in the world. Each year, roughly 188,000 people receive a diagnosis. About 543,000 are living with it globally. The disease remains incurable, and four out of every ten patients die within five years. The cancer arises from plasma cells that multiply unchecked in the bone marrow, and while treatments have improved, most patients eventually stop responding to them. When that happens, options narrow. The first patient in the KOALA trial was someone for whom standard treatments no longer worked and who was not eligible for other CAR-T therapies—the cutting-edge cell therapies that have transformed outcomes for some blood cancer patients.

But existing CAR-T treatments carry a brutal trade-off. The most effective ones target a receptor called BCMA, which appears on both cancerous and healthy immune cells. Destroying the cancer means destroying protective immune function too. More than half of patients who don't see their cancer progress end up dying from infections—pneumonia, opportunistic pathogens—rather than from the myeloma itself. The immune system, weakened by the very therapy meant to save them, becomes a liability.

HaemaLogiX's KMCAR™ therapy works differently. It targets the Kappa Myeloma Antigen, a receptor found only on kappa-type myeloma cells. Healthy immune cells don't express it. The treatment begins with a blood draw. T cells are harvested and sent to a manufacturing facility—Cell Therapies Pty Ltd, a TGA-licensed operation partnered with Peter Mac—where they are genetically modified to recognize KMA. The engineered cells are then infused back into the patient. They circulate, find the cancer cells, and destroy them. Everything else is left alone.

The first patient tolerated the initial dose well. No serious adverse events were reported. That matters. It means the therapy did what it was designed to do: it worked without triggering the cascade of complications that have haunted earlier approaches. A second patient has already been enrolled in the KOALA trial and is scheduled to receive a higher dose. This is a dose-escalation study, the standard way to find the right therapeutic window—enough drug to be effective, not so much that toxicity becomes unmanageable.

The KMCAR™ technology itself grew out of earlier work. HaemaLogiX developed a monoclonal antibody called KappaMab™ that targets the same antigen. That antibody has been tested in Phase 1, 2a, and 2b trials and showed a favorable safety profile with no antibody-related immune cell depletion and durable responses in patients. The CAR-T version is the next evolution—taking that validated target and weaponizing it with cell therapy.

Professor Simon Harrison, who directs the Centre of Excellence in Cellular Immunotherapy at Peter Mac, framed the significance plainly: if the trial confirms what the early data suggests, this could represent a meaningful advance. A therapy that controls cancer without dismantling immune defense would change the calculus for patients with relapsed or refractory disease. Dr. Rosanne Dunn, HaemaLogiX's Chief Scientific Officer, called the first patient's safe treatment an important step—the moment when laboratory work becomes human reality, when theory meets the body and holds.

The trial is registered and ongoing. A second patient is waiting. The question now is whether that first patient's good fortune will hold, whether the higher dose in the second patient will be equally well-tolerated, and whether the therapy will actually shrink tumors. Multiple myeloma remains incurable, but for patients running out of options, a treatment that might work without destroying the immune system they need to survive is worth watching.